Sustained molecular remission after low dose gemtuzumab-ozogamicin in elderly patients with advanced acute promyelocyte leukemia

Massimo Breccia, Giuseppe Cimino, Daniela Diverio, Fabiana Gentilini, Franco Mandelli, Francesco Lo Coco

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

We report here a preliminary experience with gemtuzumab ozogamicin (GO) used at low dosage (3 mg/m2) in 3 elderly patients with acute promyelocytic leukaemia (APL) who presented molecular relapse and were unfit for intensive chemotherapy.

Original languageEnglish
Pages (from-to)1273-1274
Number of pages2
JournalHaematologica
Volume92
Issue number9
DOIs
Publication statusPublished - Sep 2007

Fingerprint

Granulocyte Precursor Cells
Acute Promyelocytic Leukemia
Leukemia
Recurrence
Drug Therapy
gemtuzumab

Keywords

  • Acute promyelocytic leukemia
  • Gentuzumab ozogamicin
  • Molecular relapse

ASJC Scopus subject areas

  • Hematology

Cite this

Sustained molecular remission after low dose gemtuzumab-ozogamicin in elderly patients with advanced acute promyelocyte leukemia. / Breccia, Massimo; Cimino, Giuseppe; Diverio, Daniela; Gentilini, Fabiana; Mandelli, Franco; Lo Coco, Francesco.

In: Haematologica, Vol. 92, No. 9, 09.2007, p. 1273-1274.

Research output: Contribution to journalArticle

Breccia, Massimo ; Cimino, Giuseppe ; Diverio, Daniela ; Gentilini, Fabiana ; Mandelli, Franco ; Lo Coco, Francesco. / Sustained molecular remission after low dose gemtuzumab-ozogamicin in elderly patients with advanced acute promyelocyte leukemia. In: Haematologica. 2007 ; Vol. 92, No. 9. pp. 1273-1274.
@article{aa85820a164e44b286e46566e70612ce,
title = "Sustained molecular remission after low dose gemtuzumab-ozogamicin in elderly patients with advanced acute promyelocyte leukemia",
abstract = "We report here a preliminary experience with gemtuzumab ozogamicin (GO) used at low dosage (3 mg/m2) in 3 elderly patients with acute promyelocytic leukaemia (APL) who presented molecular relapse and were unfit for intensive chemotherapy.",
keywords = "Acute promyelocytic leukemia, Gentuzumab ozogamicin, Molecular relapse",
author = "Massimo Breccia and Giuseppe Cimino and Daniela Diverio and Fabiana Gentilini and Franco Mandelli and {Lo Coco}, Francesco",
year = "2007",
month = "9",
doi = "10.3324/haematol.11329",
language = "English",
volume = "92",
pages = "1273--1274",
journal = "Haematologica",
issn = "0390-6078",
publisher = "NLM (Medline)",
number = "9",

}

TY - JOUR

T1 - Sustained molecular remission after low dose gemtuzumab-ozogamicin in elderly patients with advanced acute promyelocyte leukemia

AU - Breccia, Massimo

AU - Cimino, Giuseppe

AU - Diverio, Daniela

AU - Gentilini, Fabiana

AU - Mandelli, Franco

AU - Lo Coco, Francesco

PY - 2007/9

Y1 - 2007/9

N2 - We report here a preliminary experience with gemtuzumab ozogamicin (GO) used at low dosage (3 mg/m2) in 3 elderly patients with acute promyelocytic leukaemia (APL) who presented molecular relapse and were unfit for intensive chemotherapy.

AB - We report here a preliminary experience with gemtuzumab ozogamicin (GO) used at low dosage (3 mg/m2) in 3 elderly patients with acute promyelocytic leukaemia (APL) who presented molecular relapse and were unfit for intensive chemotherapy.

KW - Acute promyelocytic leukemia

KW - Gentuzumab ozogamicin

KW - Molecular relapse

UR - http://www.scopus.com/inward/record.url?scp=36349001200&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=36349001200&partnerID=8YFLogxK

U2 - 10.3324/haematol.11329

DO - 10.3324/haematol.11329

M3 - Article

C2 - 17768126

AN - SCOPUS:36349001200

VL - 92

SP - 1273

EP - 1274

JO - Haematologica

JF - Haematologica

SN - 0390-6078

IS - 9

ER -